A 6-hydroxydopamine in vivo model of Parkinson's disease

Methods Mol Biol. 2012:846:355-64. doi: 10.1007/978-1-61779-536-7_30.

Abstract

Animal models of Parkinson's disease are essential to explore pathophysiological hypotheses and to test new treatment options, including neurotrophic factors. Catecholaminergic neurotoxins used to generate such models are 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. These neurotoxins predominantly kill dopaminergic neurons through oxidative damage and mitochondrial failure, although 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine fails to induce a significant dopaminergic neurodegeneration in rats. The present chapter describes a protocol for the 6-hydroxydopamine rat model based on stereotaxic injection performed only unilaterally, which mimics an early-to-mid stage of the disease.

MeSH terms

  • Animals
  • Disease Models, Animal*
  • Dopaminergic Neurons / drug effects*
  • Oxidopamine / administration & dosage
  • Oxidopamine / toxicity*
  • Parkinson Disease, Secondary / chemically induced*
  • Parkinson Disease, Secondary / surgery*
  • Rats

Substances

  • Oxidopamine